Abstract

Inflammation is a physiological process whose deregulation causes some diseases including cancer. Nuclear Factor kB (NF-kB) is a family of ubiquitous and inducible transcription factors, in which the p65/p50 heterodimer is the most abundant complex, that play critical roles mainly in inflammation. Glucocorticoid Receptor (GR) is a ligand-activated transcription factor and acts as an anti-inflammatory agent and immunosuppressant. Thus, NF-kB and GR are physiological antagonists in the inflammation process. Here we show that in mice and humans there is a spliced variant of p65, named p65 iso5, which binds the corticosteroid hormone dexamethasone amplifying the effect of the glucocorticoid receptor and is expressed in the liver of patients with hepatic cirrhosis and hepatocellular carcinoma (HCC). Furthermore, we have quantified the gene expression level of p65 and p65 iso5 in the PBMC of patients affected by SARS-CoV-2 disease. The results showed that in these patients the p65 and p65 iso5 mRNA levels are higher than in healthy subjects. The ability of p65 iso5 to bind dexamethasone and the regulation of the glucocorticoid (GC) response in the opposite way of the wild type improves our knowledge and understanding of the anti-inflammatory response and identifies it as a new therapeutic target to control inflammation and related diseases.

Details

Title
A new p65 isoform that bind the glucocorticoid hormone and is expressed in inflammation liver diseases and COVID-19
Author
Spinelli Gaetano 1 ; Biddeci Giuseppa 2 ; Artale, Anna 2 ; Valentino, Francesca 2 ; Tarantino Giuseppe 3 ; Gallo, Giuseppe 4 ; Gianguzza Fabrizio 4 ; Conaldi Pier Giulio 5 ; Corrao Salvatore 6 ; Gervasi, Francesco 7 ; Aronica, Tommaso Silvano 8 ; Di Leonardo Aldo 4 ; Duro Giovanni 2 ; Di Blasi Francesco 2 

 Istituto per la Ricerca e l’Innovazione Biomedica del Consiglio Nazionale delle Ricerche, Palermo, Italy; Università degli Studi di Palermo, Dipartimento Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517) 
 Istituto per la Ricerca e l’Innovazione Biomedica del Consiglio Nazionale delle Ricerche, Palermo, Italy (GRID:grid.10776.37) 
 Università di Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758) 
 Università degli Studi di Palermo, Dipartimento Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517) 
 Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione, Dipartimento di Ricerca, IRCCS-ISMETT, Palermo, Italy (GRID:grid.419663.f) (ISNI:0000 0001 2110 1693) 
 Azienda Ospedaliera di Rilevanza Nazionale e Alta Specializzazione ARNAS Civico, Unità COVID, Dipartimento di Medicina Interna, Palermo, Italy (GRID:grid.419995.9); Università degli Studi di Palermo, Dipartimento PROMISE, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517) 
 Rilevanza Nazionale e Alta Specializzazione Ospedaliera Trust ARNAS Civico, Laboratorio Specialistico di Oncologia, Palermo, Italy (GRID:grid.419995.9) 
 Rilevanza Nazionale e Alta Specializzazione ARNAS Civico, Unità Organizzativa Complessa di Patologia Clinica, Palermo, Italy (GRID:grid.419995.9) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2602335153
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.